Phil Deschamps | Chairman, President and Chief Executive Officer |
Sukhvinder Kalsi-Ryan | Affiliate Scientist, Kite Research Institute; and Member of the University Health Network |
Joyce LaViscount | Chief Financial Officer and Chief Operations Officer |
Jeff Porter | Porter Capital |
Anthony Lamport | The Lambda Funds |
Good evening, ladies and gentlemen, and welcome to the Fourth Quarter of Fiscal Year 2019 Earnings Conference Call for Helius Medical Technologies. At this time, all participants have been placed in a listen-only mode. Please note, this conference call is being recorded and that the recording will be available on the company’s website for replay shortly.
Before we began, I’d like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management, including statements regarding the potential FDA marketing authorization of the PoNS device, the success of the company’s planned study, the future commercialization of the PoNS treatment, expected future clinical and regulatory time lines, the potential receipt of regulatory clearance of PoNS device in the United States and projected financial results.
These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent Annual Report on Form 10-K, as well as the most recent 10-Q filing.